Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $10.00.

Several equities analysts have issued reports on the stock. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Piper Sandler raised their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, Truist Financial boosted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd.

Amneal Pharmaceuticals Trading Up 2.4 %

Shares of NASDAQ:AMRX opened at $8.06 on Thursday. The firm has a 50 day simple moving average of $8.24 and a 200-day simple moving average of $8.03. The company has a market capitalization of $2.50 billion, a PE ratio of -11.85 and a beta of 1.10. Amneal Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $9.48.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 17,410 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the sale, the director now owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. The trade was a 0.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the transaction, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The disclosure for this sale can be found here. 17.46% of the stock is owned by company insiders.

Institutional Trading of Amneal Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in Amneal Pharmaceuticals by 20.7% during the second quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock worth $4,771,000 after buying an additional 128,772 shares during the period. Rhumbline Advisers increased its stake in Amneal Pharmaceuticals by 14.9% in the 2nd quarter. Rhumbline Advisers now owns 233,217 shares of the company’s stock valued at $1,481,000 after purchasing an additional 30,286 shares in the last quarter. Acadian Asset Management LLC increased its stake in Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after purchasing an additional 710,598 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Amneal Pharmaceuticals during the second quarter worth $42,000. Finally, Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals by 17.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after purchasing an additional 641,405 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.